Infugem Patent Expiration

INFUGEM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution
Jul, 2033

(8 years from now)

Infugem is a drug owned by Sun Pharmaceutical Industries Ltd. Infugem uses Gemcitabine Hydrochloride as an active ingredient. Infugem was launched by Sun Pharm in 2018. It is is available in solution form for intravenous use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 01, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 July, 2018

Treatment: NA


More Information on Dosage

INFUGEM family patents

Family Patents